The way prescription medical devices reach consumers is changing, and Osteoboost’s national television campaign offers a revealing example of that shift. In September 2026, the maker of an FDA-cleared wearable for low bone density launched its first national TV advertisement. However, instead of telling viewers to ask their doctors about treatment, the commercial directed them to a website. From there, consumers could explore clinical information, order the device, and obtain a prescription through their physician or a telehealth provider. For pharmaceutical marketers, the campaign offers a fresh perspective on prescription device marketing and the changing path from advertising to treatment.
Table of Contents
- Osteoboost’s TV Campaign Breaks the Traditional Pharma Funnel
- How Osteoboost Connects TV Advertising, Digital Education, and Telehealth
- What Pharmaceutical Marketers Can Learn From Osteoboost
- Building a Better Patient Conversion Strategy
- Conclusion
- Frequently Asked Questions
Osteoboost’s TV Campaign Breaks the Traditional Pharma Funnel
For decades, pharmaceutical advertising has followed a familiar formula. A consumer sees a television commercial, recognizes a possible health concern, and asks a physician about the advertised treatment.
Osteoboost is testing a different approach.
The wearable device uses targeted vibration therapy to help reduce the decline in bone strength and density in certain postmenopausal women with osteopenia. The FDA granted the Osteoboost Belt De Novo marketing authorization in January 2024, establishing its classification as a Class II medical device. Importantly, its clinical study did not evaluate fracture risk.
According to a September 25, 2026, MediaPost report, Osteoboost launched television advertising across networks including Hallmark Family, ION Mystery, and Reelz. The company developed the advertisement internally, while DirectAvenue handled media placement.
Unlike many traditional pharmaceutical commercials, the Osteoboost advertisement encouraged viewers to visit ShopOsteoboost.com rather than immediately contact their doctors.
This changes the role of television advertising. Instead of simply generating awareness and encouraging physician conversations, television becomes the starting point for a broader digital experience.
Osteoboost CEO Laura Yecies also reported that the company achieved its highest weekend sales to that point following the campaign’s launch. However, that result does not establish how much additional demand television generated.
Nevertheless, the campaign demonstrates how mass media can connect directly to digital patient education and purchasing activity.
How Osteoboost Connects TV Advertising, Digital Education, and Telehealth
The most interesting part of Osteoboost’s strategy is not the television advertisement itself. Instead, it is what happens after someone visits the website.
Consumers can review product information, examine clinical evidence, explore pricing, and understand how the wearable fits into daily life.
This matters because Osteoboost is not a typical impulse purchase. The device costs approximately $1,000, requires a prescription, and involves wearing a therapeutic belt for 30 minutes daily.
Consequently, education plays an essential role in helping patients understand the product before making a financial commitment.
According to Osteoboost’s prescription information, consumers can obtain prescriptions through their existing healthcare providers or request an online evaluation through telehealth partner Beluga Health. The online option does not require a video appointment.
Interestingly, MediaPost reported that approximately 15% of Osteoboost buyers used the telehealth option. The remaining buyers relied on their personal physicians.
That finding challenges a common assumption about digital healthcare marketing. Offering telehealth does not necessarily mean replacing established physician relationships.
Rather, an effective digital experience can provide multiple routes to treatment.
Patients who already have trusted doctors can continue using them. Meanwhile, consumers who need another route to clinical evaluation may benefit from the online option.
There is also an important distinction between ordering and treatment access. Osteoboost allows customers to reserve a device before receiving a prescription, but shipment requires prescription confirmation.
For marketers, this creates a hybrid conversion model that combines online purchasing with clinical oversight.
What Pharmaceutical Marketers Can Learn From Osteoboost
Osteoboost’s campaign offers valuable lessons for pharmaceutical companies looking to connect advertising, patient education, and access to treatment.
First, traditional television remains relevant when it reaches the right audience.
Although digital advertising attracts significant attention, Osteoboost selected television networks that align with its target demographic of postmenopausal women over 50.
Previously, the brand relied primarily on Facebook advertising. Therefore, television represented an expansion of its audience strategy rather than a complete replacement of digital channels.
Second, patient education can become a central conversion tool.
Consumers considering unfamiliar treatments often have practical questions about clinical evidence, eligibility, cost, and daily use.
A website that answers those questions clearly may reduce uncertainty and encourage more informed conversations with healthcare professionals.
Third, marketers should recognize that physician involvement and digital convenience can coexist.
The 15% telehealth figure suggests that alternative prescribing pathways can serve a meaningful segment without becoming the dominant route.
However, pharmaceutical marketers cannot simply copy the model without considering important regulatory differences.
Prescription medicines and medical devices have distinct advertising requirements, clinical considerations, and distribution rules. Furthermore, digital convenience must never compromise appropriate medical evaluation.
The lesson is not to remove clinicians from the treatment journey. Instead, it is to make that journey easier to understand and navigate.
Building a Better Patient Conversion Strategy
For marketers, the next step is understanding how to measure a patient journey that moves across television, websites, physicians, and telehealth.
Traditional advertising metrics such as reach and impressions remain useful. However, they reveal only part of the picture.
Brands should also examine educational engagement, qualified inquiries, prescription completion, purchase conversion, and patient support needs.
For example, a consumer might see a television advertisement, visit the website several times, attend an educational webinar, and eventually discuss treatment with a physician.
That journey may take weeks. Consequently, judging campaign performance only through immediate online sales risks overlooking important outcomes.
Additionally, marketers need to understand where patients experience friction. Confusing eligibility information, unexpected costs, and complicated prescription instructions can discourage otherwise interested consumers.
Clear content, accessible clinical resources, and straightforward next steps may help address these concerns.
Experienced healthcare marketing partners, including eHealthcare Solutions, can support strategies connecting audience engagement with educational experiences.
Still, successful measurement requires careful privacy practices. Health-related audience data and sensitive patient information demand particular attention.
For brands examining emerging digital healthcare strategies, the broader discussion at Pharma Marketing Network highlights why the relationship between advertising, technology, and patient engagement continues to matter.
The opportunity for pharmaceutical brands is to create a more coordinated experience while protecting clinical independence and patient trust.
Conclusion
Osteoboost’s national television campaign shows how advertising for prescription medical devices is evolving. Awareness no longer needs to lead immediately to a doctor’s office. Instead, consumers can move through digital education, product evaluation, online ordering, and appropriate clinical review.
The campaign also shows that telehealth and traditional physicians can support the same commercial journey.
For pharmaceutical marketers, the broader lesson is clear: effective campaigns must connect consumer interest with credible information and practical next steps.
Ultimately, the future of healthcare marketing may depend less on where patients first encounter an advertisement and more on how confidently they can navigate everything that follows.
Frequently Asked Questions
How Are Prescription Medical Devices Marketed to Consumers?
Companies market prescription medical devices through consumer advertising, clinical education, physician outreach, and digital engagement. These activities help eligible patients understand treatment options while maintaining appropriate medical oversight.
Why Is Osteoboost’s Television Campaign Different From Traditional Pharmaceutical Advertising?
Osteoboost’s campaign directs viewers to an educational and purchasing website rather than making an immediate physician consultation its main call to action. However, a valid prescription remains necessary before the device can ship.
How Does Telehealth Fit Into Osteoboost’s Marketing Strategy?
Osteoboost offers an optional online evaluation through Beluga Health. This provides another route to a prescribing clinician. According to September 2026 reporting, approximately 15% of buyers used this option.
Can Pharmaceutical Companies Adopt the Osteoboost Marketing Model?
Pharmaceutical companies can apply elements such as connected media campaigns, educational websites, clearer patient journeys, and digital support. However, prescription-drug advertising rules, distribution restrictions, and medical oversight requirements may limit direct adoption.
What Metrics Matter Most in Prescription Wearable Marketing?
Useful metrics include website engagement, educational content consumption, qualified patient inquiries, prescription completion, purchasing activity, and patient support outcomes. Together, these measures provide a broader picture than advertising reach or immediate sales alone.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
